ArticleNeurosurgery2020
A Prognostic Gene-Expression Signature and Risk Score for Meningioma Recurrence After Resection.
Article in Neurosurgery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- European Association of Neuro-Oncology guideline on molecular testing of meningiomas for targeted therapy selection.Neuro-oncology · 2025Guideline
- LTBP2 promotes meningioma progression by enhancing glycolysis via the PI3K/AKT/mTOR/c-Myc signaling pathway.Discover oncology · 2025Article
- Determining the Biological Features of Aggressive Meningioma Growth with Transcriptomic Profiling.Cancers · 2025Article
- cIMPACT-NOW update 8: Clarifications on molecular risk parameters and recommendations for WHO grading of meningiomas.Neuro-oncology · 2025Review
- RNA splicing as a biomarker and phenotypic driver of meningioma DNA-methylation groups.Neuro-oncology · 2024Article
- The Evolving Classification of Meningiomas: Integration of Molecular Discoveries to Inform Patient Care.Cancers · 2024Review
- Radiotherapy and radiosurgery for meningiomas.Neuro-oncology advances · 2023Article
- Gene expression analysis during progression of malignant meningioma compared to benign meningioma.Journal of neurosurgery · 2023Article
- Hypermitotic meningiomas harbor DNA methylation subgroups with distinct biological and clinical features.Neuro-oncology · 2023Article
- Inhibition of the epigenetically activated miR-483-5p/IGF-2 pathway results in rapid loss of meningioma tumor cell viability.Journal of neuro-oncology · 2023Article
- Molecular classification and grading of meningioma.Journal of neuro-oncology · 2023Review
- Case Report: Recurrent meningioma with multiple metastases.Frontiers in oncology · 2023Article
- Radiotherapy for meningiomas.Journal of neuro-oncology · 2022Review
- Meningioma DNA methylation groups identify biological drivers and therapeutic vulnerabilities.Nature genetics · 2022Article
- Synthesizing Molecular and Immune Characteristics to Move Beyond WHO Grade in Meningiomas: A Focused Review.Frontiers in oncology · 2022Review
- Genomic markers of recurrence risk in atypical meningioma following gross total resection.Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 1 institution in 1 country.
Funding
Abstract
backgroundPrognostic markers for meningioma are needed to risk-stratify patients and guide postoperative surveillance and adjuvant therapy.
objectiveTo identify a prognostic gene signature for meningioma recurrence and mortality after resection using targeted gene-expression analysis.
methodsTargeted gene-expression analysis was used to interrogate a discovery cohort of 96 meningiomas and an independent validation cohort of 56 meningiomas with comprehensive clinical follow-up data from separate institutions. Bioinformatic analysis was used to identify prognostic genes and generate a gene-signature risk score between 0 and 1 for local recurrence.
resultsWe identified a 36-gene signature of meningioma recurrence after resection that achieved an area under the curve of 0.86 in identifying tumors at risk for adverse clinical outcomes. The gene-signature risk score compared favorably to World Health Organization (WHO) grade in stratifying cases by local freedom from recurrence (LFFR, P < .001 vs .09, log-rank test), shorter time to failure (TTF, F-test, P < .0001), and overall survival (OS, P < .0001 vs .07) and was independently associated with worse LFFR (relative risk [RR] 1.56, 95% CI 1.30-1.90) and OS (RR 1.32, 95% CI 1.07-1.64), after adjusting for clinical covariates. When tested on an independent validation cohort, the gene-signature risk score remained associated with shorter TTF (F-test, P = .002), compared favorably to WHO grade in stratifying cases by OS (P = .003 vs P = .10), and was significantly associated with worse OS (RR 1.86, 95% CI 1.19-2.88) on multivariate analysis.
conclusionThe prognostic meningioma gene-expression signature and risk score presented may be useful for identifying patients at risk for recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.